In a recent development, Cingulate Inc., a Delaware-incorporated pharmaceutical company, announced the dismissal of charges ...

We've all experienced it: you're in the middle of a conversation, searching for a word, a name, or a title, and… nothing. You ...

H.C. Wainwright raised the firm’s price target on Cingulate (CING) to $20 from $8 and keeps a Buy rating on the shares to reflect the recent ...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products.

Cingulate (CING) announced that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.

Cingulate Inc. (NASDAQ:CING – Free Report) – Equities research analysts at HC Wainwright issued their Q4 2024 EPS estimates for shares of Cingulate in a report issued on Thursday, January 30th.

Stock analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Cingulate in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst R.

制药公司Cingulate Inc.（特拉华州注册）近日宣布，其首席执行官兼董事长Shane Schaffer的相关指控已被撤销。该法律事件最初于2024年10月4日披露，并于2025年1月28日得到解决。这一信息于周一通过向美国证券交易委员会提交的8-K表格公布。根据InvestingPro数据显示，该公司股票在过去一年下跌超过71%，但仍保持7.35的强劲流动比率。

周四，H.C. Wainwright将Cingulate（纳斯达克股票代码：CING）的股票目标价从之前的8.00美元大幅上调至20.00美元。该公司维持对该股票的买入评级，其目标价位于分析师8美元至75美元的更广泛预测范围内。根据 InvestingPro ...

Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...